Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?

Current Opinion in Lipidology

Volumn 11, Issue 6, 2000, Pages 627-637

  Von Eckardstein, Arnold ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; CHEMICAL REACTION KINETICS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; GENETIC ASSOCIATION; HUMAN; IMMOBILIZATION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; OBESITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; ALGORITHMS; ANIMALS; BODY MASS INDEX; CHOLESTEROL, HDL; CORONARY DISEASE; ESTROGENS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NIACIN; RISK;

EID: 0033668998     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200012000-00010     Document Type: Review

References (119)

1. Current concepts: High density lipoproteins - The clinical implications of recent studies
2. Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention
3. Atheroprotective mechanisms of HDL
4. High density lipoproteins in health and disease
5. Cell cholesterol efflux: Integration of old and new observations provides new insights
6. Paraoxonase and coronary heart disease
7. Does paraoxonase play a role in susceptibility to cardiovascular disease?
8. Oxidation of high density lipoproteins II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins A-I and apo A-II
9. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells
10. High-density lipoproteins differentially modulate cytokine-induced expression of E-selectin and cyclooxygenase-2
11. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL
12. Evidence that high density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation
13. 3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate
14. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo
15. Coronary heart disease: Reducing the risk. The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view
16. The second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
17. New perspectives on the management of low levels of high density lipoprotein cholesterol
18. Relation of components of insulin resistance to coronary disease risk
19. Pharmacologic therapy for type 2 diabetes mellitus
20. Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study
21. Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL-cholesterol
22. The Munster Heart Study (PROCAM): Total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers
23. Epidemiolgical aspects of high density lipoprotein cholesterol
24. Physiological role and clinical relevance of high-density lipoprotein subclasses
25. Remodelling of high density lipoproteins by plasma factors
26. Familial HDL deficiency syndromes
27. Lack of Apo A-I is not associated with increased susceptibility to atherosclerosis in mice
28. Transgenic animals with altered high density lipoprotein composition and functions
29. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models
30. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
31. Peroxisome proliferator activated receptor alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis
32. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate
33. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans
34. Recombinant apolipoproteins for the treatment of vascular diseases
35. Gene targets and approaches for raising HDL
36. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: Evidence of a potentially relevant species-specific interaction with diet
37. Decreased susceptibility to diet induced atherosclerosis in human apolipoprotein A-II transgenic mice
38. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV
39. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse ApoA-IV
40. Clearance of cationized LDL cholesterol from a muscle depot is not enhanced in human apolipoprotein A-IV transgenic mice
41. Human apoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum
42. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease
43. ABC1-mediated transport of cellular cholesterol to HDL and apolipoproteins
44. Phospholipid transfer protein in lipid metabolism
45. Lecithin:cholesterol acyltransferase: Role in lipid metabolism, reverse cholesterol transport and atherosclerosis
46. Familial high density lipoprotein deficiency: Tangier disease
47. Mutations in ABCA1 in Tangier disease and familial high density lipoprotein deficiency
48. The gene encoding ATP binding cassette transporter 1 is mutated in Tangier disease
49. Tangier disease is caused by mutations in the gene encoding ATP binding cassette transporter 1
50. Human ATP binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred
51. The Tangier disease gene product controls the cellular apolipoprotein-mediated lipid removal pathway
52. Transport of lipids from Golgi to plasma membrane is defective in Tangier disease. Patients and Abc1-deficient mice
53. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1
54. Homozygous Tangier disease and cardiovascular disease
55. Complete genomic sequence of the human ABCA1 gene: Analysis of the human and mouse ATP binding cassette A promoter
56. Sterol-dependent transactivation of the ABC1 promoter by LXR/RXR. LXRs transactivate ABC1 promoter
57. Molecular cloning of the human ATP binding cassette transporter 1 (hABC1): Evidence for sterol-dependent regulation in macrophages
58. Interferon-γ induces downregulation of Tangier disease gene (ATP binding cassette transporter 1) in macrophage-derived foam cells
59. The ABC-A subclass of mammalian transporters
60. ABC1 promotes engulfment of apoptotic cells and transbilayer redistribution of phosphatidylserine
61. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice
62. Increased pre-β-high density lipoprotein, apolipoprotein A-I, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein A-I transgenes
63. Targeted mutation of plasma phospholipid transfer protein markedly reduces high density lipoprotein levels
64. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice
65. Charting the fate of the good cholesterol: Identification and characterization of the high density lipoprotein receptor SR-BI
66. The role of high-density lipoprotein receptor SR-BI in cholesterol metabolism
67. Apolipoprotein E and atherosclerosis
68. 1999 George Lyman Duff Memorial Lecture: Lipid transfer proteins, HDL metabolism and atherogenesis
69. Hepatic lipase: New insights from genetic and metabolic studies
70. Hepatic lipase and HDL metabolism
71. Endothelial lipase: A new member of the triglyceride lipase gene family
72. Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene
73. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse
74. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
75. Scavenger receptor B1 mediates free cholesterol flux independent of HDL tethering to the cell surface
76. In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells
77. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptors B1
78. Decreased selective uptake of high density lipoprotein cholesterylesters in apolipoprotein E knockout mice
79. Low hepatic lipase activity is a risk factor for coronary artery disease
80. Effects of testosterone replacement on HDL subtractions and apolipoprotein A-I containing lipoproteins
81. Macrophages, lipoprotein metabolism, and atherosclerosis: Insights from murine bone marrow transplantation studies
82. Apolipoprotein E dependent cholesterol efflux from macrophages: Kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E
83. Endogenous apolipoprotein E modulates cholesterol efflux and cholesterol ester hydrolysis mediated by high density lipoprotein and lipid, free apolipoproteins in mouse peritoneal macrophages
84. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase
85. Cell-derived apolipoprotein E particles inhibit VCAM expression in human endothelial cells
86. Overexpression and accumulation of apoE as a cause of hypertriglyceridemia
87. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element
88. Elevated HDL cholesterol is a risk factor for ischemic heart disease in White women when caused by a common mutation in the cholesteryl ester transfer protein gene
89. Association of cholesteryl ester protein TaqIB polymophism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham Study
90. Vaccine induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis
91. Increased atherosclerosis in ApoE and LDL receptor gene knockout mice as a result of human cholesteryl ester transfer protein transgene expression
92. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene
93. A novel endothelial derived lipase that modulates HDL metabolism
94. Cloning of unique lipase from endothelial cells extends the lipase gene family
95. Associations of obesity markers, insulin, and sex hormones with HDL, cholesterol levels in Turkish and German individuals
96. Weight loss and plasma lipids
97. Exercise intensity: Its effects on high density lipoprotein profile
98. Differential effect of National Cholesterol Education Program Step 2 diet on HDL cholesterol, its subfractions and apolipoprotein A-I levels in hypercholesterolemic women and men after 1 year. The beFIT Study
99. Treatment of hypertriglyceridemia and combined hyperlipidemia with a diet rich in mono-unsaturated and n-3 polyunsaturated acids
100. Stable isotope turnover of apolipoproteins of high density lipoproteins in humans
101. Dietary restriction of saturated fat and cholesterol decreases HDL apo A-I secretion
102. Relation between baseline and on treatment parameters and first acute major coronary events in the Air Force/Texas Coronary Atheroscelrosis Prevention Study (AFCAPS/TexCAPS)
103. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study
104. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
105. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol
106. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study implications for treatment
107. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study)
108. Clinical efficacy and safety of cerivastatin: Summary of pivotal phase IIb/III studies
109. Effects of high doses of simvastatin and atorvastatin on high density lipoprotein cholesterol and apolipoprotein A-I
110. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG CoA reductase inhibition in healthy subjects and a patient with coronary artery disease
111. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles
112. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors
113. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
114. Lipoprotein responses to treatment with lovastatin, gemfibrozil and nicotinic acid in normolipidemic patients with hypoalphalipo-proteinemia
115. Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin
116. Hormone replacement therapy, heart disease, and other considerations
117. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
118. The Women's Health Initiative: A heart-to-HRT conversation
119. Regulation of absorption and ABC1 mediated efflux of cholesterol by RXR heterodimers